Medical Xpress - latest medical and health news stories

Medical Xpress - latest medical and health news stories

by CUNY Advanced Science Research Center This atomic illustration shows the newly identified CDTB component of the binary C. diff toxin, which researchers now know attaches to the surface of human cells and injects the CDTA portion of the toxin inside the cell. Credit: Xingjian Xu and Edwin Pozharski A newly published paper in PNAS details a research breakthrough that provides a promising starting point for scientists to create drugs that can cure C. diff —a virulent health care-associated infection that causes severe diarrhea, nausea, internal bleeding, and potentially death. The bacteria affects roughly half-a-million Americans and causes nearly 15,000 deaths in the U.S. annually. Overuse of antibiotics has increasingly put patients in heath care facilities at risk for acquiring C. diff and made some strains of the bacteria particularly hard to treat. But newly discovered information about a type of toxin released by the most dangerous strains of C. diff is providing researchers with a map for developing drugs that can block the toxin and prevent the bacteria from entering human cells . "The most dangerous strains of C. diff release a binary toxin that first binds to cells and then creates a pore-forming channel that allows the toxin to get inside and do harm," said Amedee de Georges, the study's principal investigator and a professor with the Advanced Science Research Center at The Graduate Center, CUNY's Structural Biology Iniative. "We were able to combine several increasingly popular biophysical imaging techniques to visualize and characterize every atom of this binary toxin and show us where they are positioned. These details provide a critical and extremely useful starting point for designing drugs that can prevent C. diff infection." Researchers used a combination of tools—cryogenic electron microscopy, X-ray crystallography, nuclear magnetic resonance , and small angle X-ray scattering—to observe and identify the C. diff toxin's structure and mode of action. Researchers believed that it is a binary toxin (meaning it needs two components to function) that might employ a similar method to anthrax toxin to enter cells. Using that as their starting point, they sought to characterize how C. diff toxin is different than anthrax. "We observed two similar but distinct forms of the C. diff toxin—one where we see the pore-forming channel and one where it is invisible," said the first author, Xingjian Xu, a Graduate Center, CUNY Ph.D. student and a researcher in de Georges' lab. "This gives us clues as to how to prevent the formation of the channel and stop the bacteria from entering the cell." Researchers also identified a novel calcium binding site on one of the C. diff toxin's domains. This type of binding structure hasn't been identified on any other similar toxins, suggesting that calcium plays a critical role in regulating the formation and transition C. diff into cells. The study's findings will guide the design of drugs targeting C. diff infections, and specifically, the more severe C. diff bacteria strains. Explore further More information: Xingjian Xu et al, Structure of the cell-binding component of the Clostridium difficile binary toxin reveals a di-heptamer macromolecular assembly, Proceedings of the National Academy of Sciences (2020). DOI: 10.1073/pnas.1919490117 Journal information: Provided by CUNY Advanced Science Research Center Citation : Researchers identify starting point for designing drugs that cure clostridium difficile (2020, January 3) retrieved 3 January 2020 from https://medicalxpress.com/news/2020-01-drugs-clostridium-difficile.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More